surmount 1 tirzepatide Tirzepatide: the SURMOUNT-1 trial by Nadia Ahmad SURMOUNT Clinical Trials Orals Session

designed FA-LP-GCK liposomes, which recognize activated macrophages with high folic acid receptor expression in rheumatoid arthritis lesions through folic acid and inhibit P-gp-mediated drug efflux through TPGS, thereby achieving oral delivery and improving targeting

Another factor is the vitamins, minerals, and medications included in the infusion

Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells

It is worth noting that our participants had a higher baseline BMI (mean 41.5 kg m 2 ) than in the STEP 1 trial (37.9 kg m 2 ), with some studies 24 showing that greater weight loss is observed with a higher baseline BMI, which may explain the greater %WL observed in our trial